CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer

2008

CHEK2 and TP53 Mutations Linked to Breast Cancer Drug Resistance

Sample size: 109 publication 10 minutes Evidence: moderate

Author Information

Author(s): Chrisanthar Ranjan, Knappskog Stian, Løkkevik Erik, Anker Gun, Østenstad Bjørn, Lundgren Steinar, Berge Elisabet O., Risberg Terje, Mjaaland Ingvil, Mæhle Lovise, Engebretsen Lars Fredrik, Lillehaug Johan Richard, Lønning Per Eystein

Primary Institution: University of Bergen, Bergen, Norway

Hypothesis

This study aims to explore the relationship between mutations in the TP53 and CHEK2 genes and resistance to epirubicin in breast cancer patients.

Conclusion

The study found that mutations in CHEK2 and TP53 are associated with resistance to epirubicin therapy in breast cancer.

Supporting Evidence

TP53 mutations were found in 21.5% of patients and were associated with lack of treatment response.
CHEK2 mutations were identified in 2.8% of patients and predicted resistance to therapy.
Combined mutations in TP53 and CHEK2 strongly predicted therapy resistance.